Reza Shojaei: Transforming Canada’s Plasma System for Greater Resilience and Self-Sufficiency
Reza Shojaei, Chief Operating Officer at Canadian Plasma Resources, shared a post on Linkedln:
”Canada’s plasma system is quietly undergoing one of its most important transformations in decades.
Rising demand for immunoglobulins, growing pressure on global supply chains, and years of heavy reliance on imported plasma-derived medicines have pushed plasma fractionation from a technical topic into a strategic health policy priority.
Three forces converging in 2025 were:
- accelerated growth in plasma-derived medicinal products (especially immunoglobulins).
- deliberate expansion of domestic plasma collection.
- regulatory and formulary modernization reshaping how these products are assessed, manufactured, and supplied.
This is not just a market story; it’s a resilience story.
In the latest issue of Blood and Plasma Pulse, we examine:
- where Canada’s plasma fractionation market truly stands today
- how public–private partnerships are re-engineering the supply chain
- why regulatory changes in 2025 matter far beyond compliance
- what still stands between policy ambition and domestic self-sufficiency
For healthcare leaders, regulators, biotech professionals, and anyone thinking about system sustainability, this transition will shape availability, access, and risk for years to come.”
Find more posts featuring Reza Shojae on Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis